ENHANCE-3: Ensifentrine versus placebo added to standard of care for prevention of COPD exacerbations

Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Ensifentrine + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Sep 2026; status: active, not recruiting.